Results 71 to 80 of about 699 (156)

Comparison of patient-controlled intravenous analgesia with oliceridine or sufentanil on postoperative pain and quality of recovery in elderly patients after thoracoscopic pulmonary resection

Shiyong laonian yixue
[Objective] To compare the efficacy of oliceridine and sufentanil for patient-controlled intravenous analgesia (PCIA) in elderly patients after thoracoscopic pulmonary surgery, and to evaluate their impact on postoperative recovery quality.
CAI Yongliang, SUN Heliang, JIANG Yihao, WANG Zhongyun   +3 more
doaj   +1 more source

Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain – A Review of Current Evidence

Journal of Pain Research, 2021
Optimal pain relief requires a balance between adequate analgesia and risk of adverse effects. Opioids remain the cornerstone for managing moderate to severe pain, but are associated with opioid-induced respiratory depression (OIRD) and gastrointestinal complications. Opioids exert their analgesic effects predominantly via G-protein signaling, however,
Hon Sen Tan, Ashraf S Habib
openaire   +3 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Beyond Opioid Comparison: Interpreting Oliceridine in Contemporary Thoracic Recovery Pathways [Letter]. [PDF]

Drug Des Devel Ther
Cheng-Wei Lu,1,2 Kuo-Chen Chang1 1Department of Anesthesiology, Far Eastern Memorial Hospital, New Taipei, Taiwan; 2Department of Mechanical Engineering, Yuan Ze University, Taoyuan, TaiwanCorrespondence: Cheng-Wei Lu, Department of Anesthesiology, Far Eastern Memorial Hospital, 21, Section 2Nan-Ya South Road, Banqiao Dist, New Taipei, Taiwan, Tel +886-
Lu CW, Chang KC.
europepmc   +3 more sources

Novel Ligands for the Orphan Receptor GPR151 Modulate Morphine Action

Genes to Cells, Volume 31, Issue 3, May 2026.
The new GPR151 ligands altered the analgesic effects of morphine. ABSTRACT GPR151 is an orphan G‐protein‐coupled receptor expressed on specific neurons. Its expression has been reported to be upregulated in the dorsal root ganglia in mouse nerve injury models, suggesting a role in pain transmission.
Hijiri Yoshida, Takashi Suto, Hiroyuki Hirano, Hiroyuki Osada, Kazuto Nunomura, Bangzhong Lin, Shigeru Saito, Shigeki Takeda   +7 more
wiley   +1 more source

Biased Agonism at MOP Opioid Receptors

, 2023
Opioids are the mainstay of pain management. Their use comes with side effects such as respiratory depression, constipation, addiction and tolerance. Opioids interact with opioid receptors; classical μ (MOP), δ (DOP) and κ (KOP) and non-classical N/OFQ ...
Ammar Azzam (11718338)
core   +1 more source

Differences of Gradient Connectivity and Ventricle Volumes in Long‐Term Sensorineural Hearing Loss Related Cognitive Impairment Correlate With Transcriptional Signatures

Human Brain Mapping, Volume 47, Issue 5, 1 April 2026.
Long‐term hearing loss with cognitive decline shows altered brain gradients, enlarged choroid plexus, and ventricles. These are linked to transcriptomic changes in synaptic, metabolic, and neurodegenerative pathways. ABSTRACT Long‐term sensorineural hearing loss (SNHL) is a prevalent condition associated with an increased risk of cognitive impairment ...
Xiao‐Min Xu, Zi‐Huai Fang, Yuting Xia, Shuo Li, Yuan Feng, Yuanqing Wu, Richard Salvi, Xindao Yin, Yu‐Chen Chen   +8 more
wiley   +1 more source

Polymyxin B Induced Acute Diaphragmatic Paralysis: A Case Report Based on Therapeutic Drug Monitoring

Pharmacology Research &Perspectives, Volume 13, Issue 6, December 2025.
ABSTRACT Polymyxin B (PMB), a last‐resort antibiotic for multidrug‐resistant Gram‐negative infections, carries significant neurotoxicity risks that remain underrecognized in clinical practice. Here, we present a case of life‐threatening diaphragmatic paralysis induced by PMB in a patient with extensive neck and mediastinal infections caused by ...
Yunli Zhang, Xiaogang Tang, Yan Li, Xia Su, Xiaohong Zhong, Zhai Huang   +5 more
wiley   +1 more source

Evaluating biased agonism of glucagon‐like peptide‐1 (GLP‐1) receptors to improve cellular bioenergetics: A systematic review

Diabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6105-6115, November 2025.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are highly effective antidiabetic and anti‐obesity agents. Recent development and optimisation of these agents includes biased agonism (selective activation of a downstream signalling pathway) of the GLP‐1 receptor, which has demonstrated greater weight‐lowering effects and improved insulin
Sabrina Wong, Gia Han Le, Christine E. Dri, Kayla M. Teopiz, Roger S. McIntyre   +4 more
wiley   +1 more source

G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

MedComm, Volume 6, Issue 10, October 2025.
G protein‐coupled receptors (GPCRs) are the dynamic protein family in the human genome. GPCR dysregulation aids in the advancement of cancer through increased migration, survival, and proliferation. Novel treatments that target GPCR signaling include orthosteric ligands, biased receptor mutants, PROTACs, and antibody–drug conjugates.
Inamu Rashid Khan, Sana Khurshid, Saud Almawash, Rakesh Kumar, Ammira S. Al‐Shabeeb Akil, Ajaz A. Bhat, Muzafar A. Macha   +6 more
wiley   +1 more source